Walleye Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

Walleye Capital’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.76M	Buy	71,149 +51,010	+253%	+$1.22M	0.01%	1574
2025 Q4	$470K	Buy	+20,139	New	+$449K	﹤0.01%	2998
2025 Q1	–	Sell	-14,183	Closed	-$296K	–	4373
2024 Q4	$296K	Sell	14,183 -234,105	-94%	-$5.03M	﹤0.01%	3437
2024 Q3	$4.94M	Buy	+248,288	New	+$4.6M	0.01%	1180
2024 Q2	–	Sell	-21,302	Closed	-$340K	–	5649
2024 Q1	$340K	Buy	+21,302	New	+$321K	﹤0.01%	3541
2023 Q4	–	Sell	-20,549	Closed	-$240K	–	5016
2023 Q3	$240K	Buy	20,549 +8,650	+73%	+$116K	﹤0.01%	3409
2023 Q2	$160K	Buy	+11,899	New	+$171K	﹤0.01%	3215
2020 Q2	–	Sell	-12,000	Closed	-$46K	–	664
2020 Q1	$46K	Buy	+12,000	New	+$49.3K	0.01%	696

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Walleye Capital's CPRX Position: Q1 2026 in Review

Walleye Capital increased its Catalyst Pharmaceutical (CPRX) stake by 253% in Q1 2026, buying an estimated $1.22M and bringing the position to 71,149 shares worth $1.76M. The position accounts for 0.01% of the portfolio, ranked #1574.

Walleye Capital first reported a position in CPRX in Q1 2020 and has held it in 8 quarters since. The position peaked at $4.94M in Q3 2024. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Walleye Capital held 71,149 shares of Catalyst Pharmaceutical worth $1.76M as of Q1 2026.
Walleye Capital bought 51,010 Catalyst Pharmaceutical shares in Q1 2026, an estimated $1.22M.
Catalyst Pharmaceutical made up 0.01% of Walleye Capital's portfolio in Q1 2026, its #1574 holding.
Walleye Capital first reported a position in Catalyst Pharmaceutical in Q1 2020 and has held it in 8 quarters since.
Walleye Capital's Catalyst Pharmaceutical position peaked at $4.94M in Q3 2024.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.